<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHLs) are often characterized by specific cytogenetic abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluate the utility of routine cytogenetic studies in 261 "<z:hpo ids='HP_0002665'>lymphoma</z:hpo> work-ups" </plain></SENT>
<SENT sid="2" pm="."><plain>These include 4 non-hematolymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and 257 hematolymphoid processes submitted over 3 years, including even those initially appearing benign by <z:mp ids='MP_0000002'>morphology</z:mp> and immunophenotyping </plain></SENT>
<SENT sid="3" pm="."><plain>About 64/257 yielded no results and 5/78 "<z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp>/<z:hpo ids='HP_0002840'>lymphadenitis</z:hpo>" were abnormal; 3 of these 5 appeared clonal [1, shortly followed by follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL)] </plain></SENT>
<SENT sid="4" pm="."><plain>Increasing FL grades showed decreased t(14;18)/increased del 6q abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>1/4 Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) (i.e., an atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) showed t(8;14) and t(14;18) (i.e., a double-hit) </plain></SENT>
<SENT sid="6" pm="."><plain>1/4 post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) showed abnormalities, confirming clonality </plain></SENT>
<SENT sid="7" pm="."><plain>One "<z:hpo ids='HP_0001978'>extramedullary hematopoiesis</z:hpo>" with a previous <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and 1 erythroblastic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> showed abnormalities, confirming <z:hpo ids='HP_0002863'>myelodysplasias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>A monocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> revealed a t(9;11)(p22;q23) </plain></SENT>
<SENT sid="9" pm="."><plain>Routine cytogenetic studies aid in "<z:hpo ids='HP_0002665'>lymphoma</z:hpo> work-ups" by (1) detecting rare abnormalities in cases without apparent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, indicating close follow-up, (2) detecting abnormalities in FL correlating with increasing grade, (3) detecting co-existent t(8;14) and t(14;18) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, indicating a worst prognosis, (4) establishing clonality in PTLD and (5) establishing diagnoses of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="C0152276" disease_type="Neoplastic Process" abbrv="">chloroma</z:e> in tissues </plain></SENT>
<SENT sid="10" pm="."><plain>The findings by the conventional karyotyping studies in many of these cases added significant data to the diagnostic cases, beyond morphologic and immunophenotypic findings, and were not amenable to directed fluorescent-in-situ hybridization studies </plain></SENT>
</text></document>